Novo Nordisk
NVO
1,277 hedge funds and large institutions have $12.4B invested in Novo Nordisk in 2026 Q1 according to their latest regulatory filings, with 150 funds opening new positions, 446 increasing their positions, 474 reducing their positions, and 274 closing their positions.
0.31% more ownership
Funds ownership: 9.3% → 9.62% (+0.31%)
6% less repeat investments, than reductions
Existing positions increased: 446 | Existing positions reduced: 474
10% less funds holding
Funds holding: 1,418 → 1,277 (-141)
23% less capital invested
Capital invested by funds: $16.1B → $12.4B (-$3.75B)
33% less call options, than puts
Call options by funds: $1.44B | Put options by funds: $2.14B
45% less funds holding in top 10
Funds holding in top 10: 20 → 11 (-9)
45% less first-time investments, than exits
New positions opened: 150 | Existing positions closed: 274
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$916M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$468M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$371M |
| 4 |
Two Sigma Investments
New York
|
+$282M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$237M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$411M |
| 2 |
Goldman Sachs
New York
|
-$278M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
-$248M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$245M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$221M |
NVO Hedge Fund Activity: Q1 2026 in Review
1,277 of the 8,172 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q1 2026, worth a combined $12.4B — down 23% from $16.1B a quarter earlier.
Sellers outnumbered buyers: 274 funds closed out of NVO and 150 opened new positions — a net loss of 124 holders — while 474 trimmed existing stakes and 446 added.
The largest buyer was Dodge & Cox, opening a new position worth an estimated $916M. The largest seller was Fidelity Investments, cutting an estimated $411M.
- 1,277 institutional investors held Novo Nordisk (NVO) as of Q1 2026, down from 1,418 in Q4 2025.
- Funds reported $12.4B of Novo Nordisk stock for Q1 2026, down 23% quarter-over-quarter.
- 150 funds opened new Novo Nordisk positions in Q1 2026 and 274 closed out, a net change of -124 holders.
- The largest Novo Nordisk buyer in Q1 2026 was Dodge & Cox, an estimated $916M added.
- The largest Novo Nordisk seller in Q1 2026 was Fidelity Investments, an estimated $411M sold.
Based on aggregated 13F filings for Q1 2026.